J
Jun Zhang
Researcher at Academy of Military Medical Sciences
Publications - 7
Citations - 2520
Jun Zhang is an academic researcher from Academy of Military Medical Sciences. The author has contributed to research in topics: Epitope & Coronavirus. The author has an hindex of 5, co-authored 7 publications receiving 1480 citations.
Papers
More filters
Journal ArticleDOI
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi Xiangyang,Renhong Yan,Jun Zhang,Zhang Guanying,Yuanyuan Zhang,Hao Meng,Zhe Zhang,Pengfei Fan,Dong Yunzhu,Yilong Yang,Chen Zhengshan,Yingying Guo,Jinlong Zhang,Yaning Li,Xiaohong Song,Chen Yi,Lu Xia,Ling Fu,Lihua Hou,Junjie Xu,Changming Yu,Jianmin Li,Qiang Zhou,Wei Chen +23 more
TL;DR: The epitope of 4A8 is defined as the N-terminal domain (NTD) of the S protein by determining with cryo–eletron microscopy its structure in complex with the Sprotein, which points to the NTD as a promising target for therapeutic mAbs against COVID-19.
Journal ArticleDOI
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Feng Cai Zhu,Xu Hua Guan,Yu-Hua Li,Jian Ying Huang,Tao Jiang,Li Hua Hou,Jing Xin Li,Bei Fang Yang,Ling Wang,W J Wang,Shi Po Wu,Zhao Wang,Xiao Hong Wu,Jun Jie Xu,Zhe Zhang,Si Yue Jia,Bu Sen Wang,Yi Hu,Jing Jing Liu,Jun Zhang,Xiao Ai Qian,Qiong Li,Hong Xing Pan,Hu Dachuan Jiang,Peng Deng,Jin Bo Gou,Xue-Wen Wang,Xing Huan Wang,Wei Chen +28 more
TL;DR: The first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study, induced significant immune responses in the majority of recipients after a single immunisation.
Journal ArticleDOI
HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry
Congwen Wei,Luming Wan,Qiulin Yan,Qiulin Yan,Xiaolin Wang,Jun Zhang,Xiaopan Yang,Yanhong Zhang,Chen Fan,Dongyu Li,Yong-Qiang Deng,Jin Sun,Jing Gong,Jing Gong,Xiaoli Yang,Yufei Wang,Xuejun Wang,Jianmin Li,Huan Yang,Huilong Li,Zhe Zhang,Rong Wang,Peng Du,Yulong Zong,Feng Yin,Wanchuan Zhang,Nan Wang,Yumeng Peng,Haotian Lin,Jiangyue Feng,Cheng-Feng Qin,Wei Chen,Qi Gao,Rui Zhang,Yuan Cao,Hui Zhong +35 more
TL;DR: The findings reveal that SR-B1 acts as a host factor that promotes SARS-CoV-2 entry and may help explain viral tropism, identify a possible molecular connection between COVID-19 and lipoprotein metabolism, and highlight SR- B1 as a potential therapeutic target to interfere with Sars-Cov-2 infection.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Shipo Wu,Jianying Huang,Zhe Zhang,Jianyuan Wu,Jinlong Zhang,Hanning Hu,Tao Zhu,Jun Zhang,Lin Luo,Pengfei Fan,Busen Wang,Chang Chen,Chen Yi,Xiaohong Song,Yudong Wang,Weixue Si,Tianjian Sun,Xinghuan Wang,Lihua Hou,Wei Chen +19 more
TL;DR: In this article, the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID19 from China was evaluated.
Posted ContentDOI
A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
Chi Xiangyang,Renhong Yan,Jun Zhang,Zhang Guanying,Yuanyuan Zhang,Hao Meng,Zhe Zhang,Pengfei Fan,Dong Yunzhu,Yilong Yang,Chen Zhengshan,Yingying Guo,Jinlong Zhang,Yaning Li,Xiaohong Song,Chen Yi,Lu Xia,Ling Fu,Lihua Hou,Junjie Xu,Changming Yu,Jianmin Li,Qiang Zhou,Wei Chen +23 more
TL;DR: A new vulnerable epitope of the S protein is discovered and promising neutralizing mAbs are identified as potential clinical therapy for COVID-19, the pandemic of coronavirus disease 2019.